- Home
- ETON vs NGS Comparison
ETON vs NGS Comparison
Compare ETON & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NGS
- Stock Information
- Founded
- ETON 2017
- NGS 1998
- Country
- ETON United States
- NGS United States
- Employees
- ETON N/A
- NGS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NGS Oilfield Services/Equipment
- Sector
- ETON Health Care
- NGS Energy
- Exchange
- ETON Nasdaq
- NGS Nasdaq
- Market Cap
- ETON 428.5M
- NGS N/A
- IPO Year
- ETON 2018
- NGS 2002
- Fundamental
- Price
- ETON $17.33
- NGS $20.11
- Analyst Decision
- ETON Strong Buy
- NGS Strong Buy
- Analyst Count
- ETON 3
- NGS 1
- Target Price
- ETON $27.67
- NGS $32.00
- AVG Volume (30 Days)
- ETON 221.4K
- NGS 71.1K
- Earning Date
- ETON 05-13-2025
- NGS 05-12-2025
- Dividend Yield
- ETON N/A
- NGS N/A
- EPS Growth
- ETON N/A
- NGS 260.53
- EPS
- ETON N/A
- NGS 1.37
- Revenue
- ETON $39,011,000.00
- NGS $156,742,000.00
- Revenue This Year
- ETON $92.33
- NGS $12.87
- Revenue Next Year
- ETON $52.62
- NGS $15.40
- P/E Ratio
- ETON N/A
- NGS $14.68
- Revenue Growth
- ETON 23.29
- NGS 29.36
- 52 Week Low
- ETON $3.18
- NGS $16.70
- 52 Week High
- ETON $18.41
- NGS $29.74
- Technical
- Relative Strength Index (RSI)
- ETON 68.29
- NGS 53.74
- Support Level
- ETON $16.43
- NGS $17.63
- Resistance Level
- ETON $17.49
- NGS $19.68
- Average True Range (ATR)
- ETON 0.88
- NGS 1.00
- MACD
- ETON 0.19
- NGS 0.28
- Stochastic Oscillator
- ETON 92.78
- NGS 90.51
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.